ERD

Sort by

European Partnerships

Show in overview

EU-Programme-Call

Show in overview

7 items found

Toggle all information

Inno4Vac | Innovations to accelerate vaccine development and manufacture

01-09-2021

28-02-2027

Show more information

Organisation SCLAVO VACCINES ASSOCIATION

TRANSVAC2 | European Vaccine Research and Development Infrastructure

01-05-2017

30-04-2023

Show more information

Organisation SCLAVO VACCINES ASSOCIATION

TRANSVAC-DS | DESIGN STUDY FOR A EUROPEAN VACCINE INFRASTRUCTURE

01-06-2020

28-02-2023

Show more information

Organisation SCLAVO VACCINES ASSOCIATION

Vacc-iNTS | Advancing a GMMA-based vaccine against invasive non-typhoidal salmonellosis through Phase 1 trial in Europe and sub-Saharan Africa

01-10-2019

31-07-2026

Show more information

Organisation SCLAVO VACCINES ASSOCIATION

VSV-EBOVAC | Vaccine safety and immunogenicity signatures of human responses to VSV-ZEBOV – Sofia ref.: 115842

01-03-2015

28-02-2019

Show more information

Organisation SCLAVO VACCINES ASSOCIATION

VSV-EBOPLUS | SYSTEMS ANALYSIS OF ADULT AND PEDIATRIC RESPONSES TO THE VSV-ZEBOV EBOLA VACCINE - Sofia ref.: 116068

01-04-2016

31-03-2023

Show more information

Organisation SCLAVO VACCINES ASSOCIATION

VacPath | Novel vaccine vectors to resist pathogen challenge

01-01-2019

31-10-2024

Show more information

Organisation SCLAVO VACCINES ASSOCIATION

Projects overview

Selected filters:

Inno4Vac | Innovations to accelerate vaccine development and manufacture

TRANSVAC2 | European Vaccine Research and Development Infrastructure

TRANSVAC-DS | DESIGN STUDY FOR A EUROPEAN VACCINE INFRASTRUCTURE

Vacc-iNTS | Advancing a GMMA-based vaccine against invasive non-typhoidal salmonellosis through Phase 1 trial in Europe and sub-Saharan Africa

VSV-EBOVAC | Vaccine safety and immunogenicity signatures of human responses to VSV-ZEBOV – Sofia ref.: 115842

VSV-EBOPLUS | SYSTEMS ANALYSIS OF ADULT AND PEDIATRIC RESPONSES TO THE VSV-ZEBOV EBOLA VACCINE - Sofia ref.: 116068

VacPath | Novel vaccine vectors to resist pathogen challenge